Targeting key genes in the LTM pathway, such as HSPA5 and CTNNB1, could offer novel approaches to enhance immune cell infiltration and restore immune surveillance in HPV-positive cervical cancer. This evidence concerns the gene CTNNB1 and cervical carcinoma.